CurrentColorado Rocky Mountain Health PlansPolicy 1 = 2025 P 1142-12

Ruconest (C1 esterase inhibitor [recombinant]) prior authorization

Prior authorization criteria and program rules for Ruconest used to treat acute hereditary angioedema (HAE) attacks; applies to members under the payer's pharmacy clinical programs and providers requesting coverage.

Policy Summary

PayerColorado Rocky Mountain Health Plans

PolicyRuconest (C1 esterase inhibitor [recombinant]) prior authorization

Policy CodePolicy 1 = 2025 P 1142-12

Change TypeClarified wordingno material change

Effective Date10/1/2025

Next Review Date

Key ActionObtain prior authorization confirming diagnosis of hereditary angioedema and that Ruconest will be used for an acute HAE attack (not in combination with other acute HAE products).

SourceLink

POLICY UPDATE CHANGES

Revised wording of criteria without change to clinical intent.

Added state mandate footnote.

2025-10-01Policy effective date

12 monthsAuthorization duration

P&T 2014-2025Reviewed annually

Coverage Criteria for Ruconest (C1 esterase inhibitor [recombinant])

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Initial authorization

Approved when ALL of the following are met:

Primary criteria: Diagnosis of hereditary angioedema (HAE).

Primary criteria: Used for the treatment of acute HAE attacks.

Primary criteria: Not used in combination with other products indicated for acute HAE attacks (e.g., Berinert, Firazyr, or Kalbitor).

Authorization issued for 12 months; state mandates and member benefit plan terms may apply.

Use of Ruconest is intended for the treatment of acute hereditary angioedema (HAE) attacks in adults and adolescents. The policy specifies that effectiveness has not been established for HAE patients with laryngeal attacks, and therefore laryngeal use is noted as a limitation of the evidence. Additionally, Ruconest must not be administered in combination with other products indicated for acute HAE attacks (for example, Berinert, Firazyr, or Kalbitor).

Re-authorization and Continuation Criteria

Re-authorization

Re-authorization and continuation rules

Re-authorization: Authorization will be issued for 12 months.

UnitedHealthcare may approve initial and re-authorization based on previous claim/medication history, diagnosis codes (ICD-10), and/or claim logic. Supply limitations may be in place.

Provider Actions and Prior Authorization Requirements

Prior Authorization

Prior Authorization Required

Prior authorization required — Member must have a diagnosis of hereditary angioedema (HAE) and be using Ruconest for acute HAE attacks. Authorization will be issued for 12 months.

Prior authorization required for Ruconest (acute HAE attacks)
Authorization duration: 12 months

Denial Risk

Triggers for Denial

Triggers for denial include use for conditions other than HAE, use for prevention or prophylaxis rather than acute treatment, and concurrent use with other products indicated for acute HAE attacks (e.g., Berinert, Firazyr, Kalbitor).

Non-HAE diagnosis
Use for prophylaxis/prevention (not acute attack)
Concurrent combination therapy with other acute HAE products (Berinert, Firazyr, Kalbitor)

Documentation Required

Documentation and Program Notes

Authorization and reauthorization decisions may be based on prior claim/medication history, submitted diagnosis codes (ICD-10), and automated claim logic. State mandates, federal regulatory requirements, and the member’s specific benefit plan may affect coverage. Other policies and utilization management programs may also apply.

Documentation may include prior medication/claim history and relevant ICD-10 diagnosis codes
Authorizations may be automated depending on program/therapeutic class
State and federal mandates and member benefit terms may alter coverage determination

Step Therapy

Step Therapy / Utilization Notes

Supply limitations and other utilization management programs may apply. Providers should verify formulary limits and step therapy requirements prior to prescribing.

Supply limitations may be applied
Step therapy or other utilization controls may be enforced

Step	Requirement / description	Notes
No explicit step therapy specified	The policy does not define step-based medication trials or prior failures required prior to approval.	Other utilization management programs may apply (e.g., approvals based on prior claim/medication history, diagnosis codes, and claim logic; supply limitations may be in place).

Background

Ruconest (C1 esterase inhibitor [recombinant]) is indicated for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema (HAE). The product labeling notes that effectiveness was not established for HAE patients with laryngeal attacks, which is an important clinical consideration when assessing appropriateness for use.

Definitions

Hereditary angioedema (HAE) — definition and relevance

DefinitionHereditary angioedema (HAE): a genetic disorder characterized by recurrent acute angioedema attacks for which C1 esterase inhibitor therapy (e.g., Ruconest) is indicated.

Relevant indicationRuconest is indicated for treatment of acute HAE attacks in adult and adolescent patients.

LimitationsEffectiveness of Ruconest was not established for HAE patients with laryngeal attacks.

Therapeutic classC1 esterase inhibitor (recombinant).

Clinical implicationA confirmed diagnosis of HAE is required for coverage consideration for acute attack treatment.